Empagliflozin ameliorates endothelial dysfunction and suppresses atherogenesis in diabetic apolipoprotein E-deficient mice

Recent studies reported cardioprotective effects of sodium glucose co-transporter 2 (SGLT2) inhibitors; however, the underlying mechanisms are still obscure. Here, we investigated whether empagliflozin attenuates atherogenesis and endothelial dysfunction in diabetic apolipoprotein E-deficient (ApoE-...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	European journal of pharmacology Ročník 875; s. 173040
Hlavní autori:	Ganbaatar, Byambasuren, Fukuda, Daiju, Shinohara, Masakazu, Yagi, Shusuke, Kusunose, Kenya, Yamada, Hirotsugu, Soeki, Takeshi, Hirata, Ken-ichi, Sata, Masataka
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Netherlands Elsevier B.V 15.05.2020
Predmet:	Adipose Tissue - drug effects Adipose Tissue - immunology Adipose Tissue - metabolism Animals Aorta, Thoracic - drug effects Aorta, Thoracic - immunology Aorta, Thoracic - pathology Atherosclerosis Benzhydryl Compounds - administration & dosage Blood Glucose - analysis Blood Glucose - drug effects Diabetes Mellitus, Experimental - blood Diabetes Mellitus, Experimental - chemically induced Diabetes Mellitus, Experimental - complications Diabetes Mellitus, Experimental - drug therapy Eicosanoids - metabolism Empagliflozin Endothelial function Endothelium, Vascular - drug effects Endothelium, Vascular - immunology Endothelium, Vascular - pathology Glucosides - administration & dosage Humans Inflammation Male Mice Mice, Knockout, ApoE Plaque, Atherosclerotic - etiology Plaque, Atherosclerotic - pathology Plaque, Atherosclerotic - prevention & control SGLT2 inhibitor Sodium-Glucose Transporter 2 Inhibitors - administration & dosage Streptozocin - toxicity Empagliflozin Inflammation Endothelial function SGLT2 inhibitor Atherosclerosis
ISSN:	0014-2999, 1879-0712, 1879-0712
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!